| Trial ID: | L0222 |
| Source ID: | NCT00368017
|
| Associated Drug: |
Pioglitazone
|
| Title: |
Metabolic Effects of Thiazolidinediones in Chronic Kidney Disease
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease
|
| Interventions: |
DRUG: pioglitazone|DRUG: placebo
|
| Outcome Measures: |
Primary: A decrease in C-reactive protein (CRP) levels, 14 weeks | Secondary: Improved insulin resistance, 14 weeks|Improved endothelium-dependent vasodilation, 14 weeks
|
| Sponsor/Collaborators: |
Sponsor: Vanderbilt University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
12
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2006-04
|
| Completion Date: |
2007-09
|
| Results First Posted: |
|
| Last Update Posted: |
2010-11-03
|
| Locations: |
Vanderbilt University Medical Center, Nashville, Tennessee, 37232, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00368017
|
